A CLINICAL TRIAL TO STUDY THE EFFECT OF SIDDHA DRUG PAVALA VEERA CHUNNAM IN PATIENTS HAVING CHOLELITHIASIS

PHASE II NON-RANDOMIZED OPEN CLINICAL EVALUATION OF SIDDHA MEDICINE PAVALA VEERA CHUNNAM FOR SATHTHI PITHAM (CHOLELITHIASIS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027900

Enrollment

Registered

2020-09-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K808- Other cholelithiasis

Interventions

Intervention1: Pavalaveera Chunnam : 65mg of Pavalaveera Chunnam is Administrated twice a day with milk for 48 days Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: Accidentally identified gall stone in USG Asymptomatic Cholelithiasis. Stone Size less than 8mm (normal lumen size is 8mm)

Exclusion criteria

Exclusion criteria: Pregnant and lactating mothers. Cholecystitis. Pancreatitis Obstructive Jaundice. Choledo Cholelithiasis Acute Cholelithiasis Gall Stone patients with other comorbidities Malignancy of gall bladder -Will be excluded clinically or based on available medical reports

Design outcomes

Primary

Measure	Time frame
Outcome is mainly assessed by reduction in clinical symptoms measured by reduction in size of gall stones with interpretation of USG abdomen.Timepoint: 48days.	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr Nikil Niva j

Government Siddha Medical College Chennai

sasirekha.siddha@gmail.com9444832728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026